Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 14/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | DUSP22 | Q9NRW4 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GRK2 | P25098 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564798 | 0.94 | PTGER4 (0.76) | PTGER4CYP1A2CYP2D6KMT2ADUSP3 | |
| SCHEMBL3562781 | 0.90 | PTGER4 (0.84) | PTGER4CYP1A2CYP2D6KMT2ADUSP3 | |
| SCHEMBL1589859 | 0.89 | PTGER4 (0.68) | PTGER4CYP1A2CYP2D6KMT2ADUSP3 | |
| SCHEMBL3561110 | 0.88 | PTGER4 (0.85) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3968229 | 0.88 | PTGER4 (0.67) | PTGER4CYP1A2CYP2D6KMT2ADUSP3 | |
| SCHEMBL4409667 | 0.88 | PTGER4 (0.88) | PTGER4CYP1A2CYP2D6KMT2ADUSP3 | |
| SCHEMBL10058522 | 0.88 | PTGER4 (0.55) | PTGER4CYP1A2CYP2D6KMT2APOLB | |
| SCHEMBL4410567 | 0.87 | PTGER4 (0.69) | PTGER4CYP1A2CYP2D6KMT2APOLB | |
| SCHEMBL3963580 | 0.87 | PTGER4 (0.69) | PTGER4CYP1A2CYP2D6KMT2A | |
| SCHEMBL3568198 | 0.86 | PTGER4 (0.71) | PTGER4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979317-B1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LTD (GB) | 2012-08-22 | — | — | EP | disclosed |
| US-20090318523-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | disclosed |
| EP-2081896-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| EP-1979317-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008061955-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007088189-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318523-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER3, HTR4 | PTGER4 1/4885CYP1A2 328/4885CYP2D6 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.